Amphista Therapeutics Revenue and Competitors

Chapelhall,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Amphista Therapeutics's estimated annual revenue is currently $14.4M per year.(i)
  • Amphista Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Amphista Therapeutics has 93 Employees.(i)
  • Amphista Therapeutics grew their employee count by 12% last year.

Amphista Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Discovery TechnologyReveal Email/Phone
3
VP Drug DiscoveryReveal Email/Phone
4
VP Intellectual PropertyReveal Email/Phone
5
Chief Technology OfficerReveal Email/Phone
6
Associate Director Medicinal ChemistryReveal Email/Phone
7
Director BioinformaticsReveal Email/Phone
8
Director OncologyReveal Email/Phone
9
Associate Director Medicinal ChemistryReveal Email/Phone
10
Chief Development OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Amphista Therapeutics?

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell's degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

keywords:N/A

N/A

Total Funding

93

Number of Employees

$14.4M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Amphista Therapeutics News

2022-04-06 - Global Targeted Protein Degradation (TPD) Market Landscape ...

AbbVie; Accelero Biostructures; Amgen; Amphista Therapeutics; AnHorn Medicines; Arvinas; Ascentage Pharma; Aurigene Discovery; AUTOTAC Bio...